10-Q: Senseonics Holdings Reports Q2 2024 Results, Revenue Growth Offset by Increased Costs

Senseonics Holdings, Inc. reported a revenue increase in Q2 2024, but also experienced a net loss due to higher operating expenses and other factors.

Summary

• Senseonics Holdings, Inc. reported a total revenue of $4.9 million for the three months ended June 30, 2024, an increase from $4.1 million in the same period of 2023.
• The company's cost of sales increased to $4.6 million, resulting in a gross profit of $0.3 million for the quarter.
• Operating loss for the quarter was $19.5 million, slightly improved from $19.9 million in the prior year.
• Net loss for the quarter was $20.3 million, compared to $20.4 million in Q2 2023.
• For the six months ended June 30, 2024, total revenue was $9.9 million, up from $8.3 million in the same period of 2023.
• The company's gross profit for the first six months of 2024 was $0.6 million, compared to $0.8 million in the prior year.
• Net loss for the first six months of 2024 was $39.2 million, compared to $19.1 million in the same period of 2023.
• The company had unrestricted cash, cash equivalents, and marketable securities of $84.6 million as of June 30, 2024.
• Senseonics has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with revenue growth but significant losses and concerns about the company's ability to continue as a going concern. The financial results are worse than the previous year, and the company's future is uncertain, leading to a negative sentiment.

Positives

• Total revenue increased for both the three and six months ended June 30, 2024, indicating growth in sales.
• Research and development expenses decreased for both the three and six months ended June 30, 2024, suggesting improved efficiency in R&D spending.
• The company has secured a loan agreement for up to $50 million, providing a source of funding.
• Medicare coverage was expanded for Eversense E3 to include all people with diabetes using insulin and non-insulin users who have a history of problematic hypoglycemia.

Negatives

• The company experienced a net loss of $20.3 million for the three months ended June 30, 2024, and $39.2 million for the six months ended June 30, 2024.
• Gross profit decreased for both the three and six months ended June 30, 2024, due to increased manufacturing costs.
• Selling, general, and administrative expenses increased for both the three and six months ended June 30, 2024.
• The company has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and the need for additional funding.
• The company is subject to patent litigation, which could be costly and disruptive.
• The company's success depends on the commercialization and adoption of its Eversense CGM systems, which is subject to regulatory approvals and reimbursement from third-party payors.
• The company relies heavily on one customer, Ascensia, for a significant portion of its revenue, creating a concentration risk.
• The company's debt obligations include covenants that require minimum cash holdings and performance milestones, which could restrict operations if not met.

Future Outlook

The company anticipates that its principal uses of cash in the future will be primarily to fund its operations, working capital needs, capital expenditures and other strategic initiatives. The company's ability to continue to fund its operations and meet capital needs will depend on its ability to successfully obtain funding from public or private debt and equity financings and other sources of capital. There is no assurance that the company will be successful in obtaining sufficient funding on acceptable terms, if at all, and could be forced to delay, reduce, or eliminate some or all of its research, clinical trials, product development or future commercialization efforts, which could materially adversely affect its business prospects or its ability to continue as a going concern.

Management Comments

• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
• Our disclosure controls and procedures are designed to provide reasonable assurance of achieving such control objectives.
• Based on the evaluation of our disclosure controls and procedures as of June 30, 2024, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Industry Context

The medical device industry, particularly the glucose monitoring sector, is characterized by intense competition, rapid technological advancements, and frequent patent litigation. Senseonics is navigating this landscape by focusing on long-term implantable CGM technology, which differentiates it from traditional non-implantable systems. The company's collaboration with Ascensia is a key part of its commercialization strategy, but also creates a reliance on a single customer. The expansion of Medicare coverage for Eversense E3 is a positive development, but the company still faces challenges in achieving profitability and securing sufficient funding.

Comparison to Industry Standards

• Senseonics' Eversense system competes with other continuous glucose monitoring systems like Dexcom and Abbott's FreeStyle Libre, which are non-implantable and require more frequent sensor replacements.
• The company's 180-day and 365-day sensor durations are a key differentiator, offering a longer wear time compared to the 7-14 day sensors of competitors.
• The company's gross margin of 6.4% for the six months ended June 30, 2024, is relatively low compared to established medical device companies, indicating potential challenges in cost management.
• The company's reliance on a single customer, Ascensia, for a significant portion of its revenue is a risk not typically seen in more diversified medical device companies.
• The company's ongoing patent litigation is a common issue in the medical device industry, where intellectual property is highly valuable and frequently contested.

Legal Proceedings

• The company is involved in a patent infringement lawsuit filed by Cellspin Soft, Inc.
• The company successfully defended against a False Claims Act lawsuit, with the Fifth Circuit affirming the dismissal of the plaintiff's lawsuit.

Related Party Transactions

• The company has significant revenue from sales to Ascensia, a related party.
• The company purchases certain medical supplies from Ascensia for its clinical trials.
• PHC has a noncontrolling ownership interest in the company and representation on the board of directors.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional funding.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers may experience disruptions in product availability or support if the company faces financial difficulties.
• Suppliers and creditors may face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company will continue to monitor its capital structure and market conditions.
• The company will seek additional funding through public or private debt and equity financings and other sources.
• The company will continue to develop and commercialize its Eversense CGM systems.
• Eon Care operations are planned to commence by the end of 2024.
• The company will continue first-in-human testing for the Gemini system.

Key Dates

Keywords

glucose monitoring, CGM, Eversense, diabetes, medical technology, implantable sensor, revenue, net loss, financial results, Ascensia, FDA approval, clinical trials